文章：

复发/难治性弥漫性大B细胞淋巴瘤：在CAR-T细胞时代，自体干细胞移植是否仍具治疗价值？

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is There Still a Role for Autologous Stem Cell Transplantation in the CAR T-Cell Era?

原文发布日期：23 May 2024

DOI: 10.3390/cancers16111987

类型: Article

开放获取: 是

英文摘要：

Recently, CD19-directed chimeric antigen receptor (CAR) T-cell therapies have revolutionized treatment strategies for diffuse large B-cell lymphoma (DLBCL). CAR T-cell therapy is increasingly used as a second-line therapy for patients with DLBCL with early relapse or refractoriness to initial chemoimmunotherapy and displaced high-dose chemotherapy, followed by autologous stem cell transplantation (ASCT) as the standard of care for these patients. However, patients with late relapse or chemosensitive disease still benefit from autologous stem cell transplantation. We will review practice-changing studies in early relapse (ZUMA-7 and TRANSFORM) under consideration of the negative BELINDA trial, with a focus on register data, comparing CAR T-cell therapy and ASCT for patients responding to salvage therapy.

摘要翻译： 

近年来，CD19导向的嵌合抗原受体（CAR）T细胞疗法已彻底改变了弥漫性大B细胞淋巴瘤（DLBCL）的治疗策略。对于早期复发或对初始化学免疫疗法无效的DLBCL患者，CAR T细胞疗法正日益被用作二线治疗，并取代了高剂量化疗联合自体干细胞移植（ASCT）作为这些患者的标准治疗方案。然而，对于晚期复发或化疗敏感的患者，自体干细胞移植仍能带来获益。在考虑BELINDA试验阴性结果的基础上，我们将回顾针对早期复发的改变临床实践的研究（ZUMA-7和TRANSFORM），重点关注注册数据，比较CAR T细胞疗法与ASCT在挽救治疗有效患者中的应用。

原文链接：

Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is There Still a Role for Autologous Stem Cell Transplantation in the CAR T-Cell Era?